Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN [NASD]
AstraZeneca PLC
Index- P/E40.42 EPS (ttm)1.22 Insider Own0.50% Shs Outstand2.62B Perf Week-0.06%
Market Cap128.62B Forward P/E15.02 EPS next Y3.27 Insider Trans0.00% Shs Float2.60B Perf Month1.59%
Income3.20B PEG2.07 EPS next Q- Inst Own15.70% Short Float3.79% Perf Quarter-2.71%
Sales26.62B P/S4.83 EPS this Y137.20% Inst Trans-6.46% Short Ratio9.26 Perf Half Y-10.11%
Book/sh5.95 P/B8.27 EPS next Y55.36% ROA5.20% Target Price63.73 Perf Year3.86%
Cash/sh3.06 P/C16.09 EPS next 5Y19.50% ROE25.10% 52W Range45.39 - 64.94 Perf YTD-1.60%
Dividend1.40 P/FCF483.55 EPS past 5Y1.70% ROI12.20% 52W High-24.25% Beta0.56
Dividend %2.85% Quick Ratio0.80 Sales past 5Y1.50% Gross Margin80.00% 52W Low8.37% ATR0.90
Employees76100 Current Ratio1.00 Sales Q/Q11.20% Oper. Margin19.40% RSI (14)47.72 Volatility1.19% 1.40%
OptionableYes Debt/Eq1.30 EPS Q/Q223.30% Profit Margin12.00% Rel Volume0.72 Prev Close49.42
ShortableYes LT Debt/Eq1.15 EarningsApr 30 BMO Payout112.50% Avg Volume10.64M Price49.19
Recom1.20 SMA20-0.95% SMA50-0.86% SMA200-6.94% Volume7,733,898 Change-0.47%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Apr-14-21 04:02AM  
02:58AM  
01:48AM  
12:04AM  
Apr-13-21 11:37PM  
08:00PM  
08:00PM  
07:01PM  
05:41PM  
05:17PM  
04:41PM  
02:09PM  
12:31PM  
11:41AM  
11:39AM  
11:31AM  
11:30AM  
11:01AM  
10:56AM  
10:51AM  
10:50AM  
10:13AM  
10:11AM  
09:43AM  
09:28AM  
09:28AM  
08:59AM  
08:14AM  
06:20AM  
04:36AM  
02:13AM  
Apr-12-21 11:41PM  
10:35PM  
09:09PM  
03:21PM  
03:02PM  
01:51PM  
11:53AM  
08:35AM  
07:15AM  
07:05AM  
02:38AM  
Apr-11-21 08:00PM  
02:20PM  
01:03PM  
10:37AM  
05:00AM  
02:20AM  
Apr-10-21 08:00PM  
08:00PM  
04:13PM  
03:17PM  
09:48AM  
06:04AM  
Apr-09-21 06:34PM  
06:21PM  
06:13PM  
05:37PM  
05:23PM  
04:33PM  
02:13PM  
01:39PM  
01:25PM  
12:12PM  
11:51AM  
11:46AM  
11:46AM  
11:02AM  
10:30AM  
10:16AM  
10:01AM  
09:55AM  
09:51AM  
09:16AM  
08:16AM  
08:16AM  
06:00AM  
05:14AM  
05:05AM  
04:33AM  
03:01AM  
02:47AM  
02:36AM  
01:53AM  
01:03AM  
Apr-08-21 11:22PM  
08:00PM  
08:00PM  
06:21PM  
06:02PM  
05:00PM  
04:53PM  
03:23PM  
03:12PM  
02:59PM  
01:54PM  
01:23PM  
12:14PM  
11:43AM  
11:25AM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; and with Massachusetts General Hospital to accelerate digital health solutions. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.